Subsidies & Funding

We empower medical innovation

Project Management

We manage your EU Horizon 2020 project

Business Strategy

We support successful commercialisation

Funding database

EU & non EU subsidies

News

Five subsidies to watch for the coming months

March 15 2016

Grants in life sciences and medical technology sectors are a highly-attractive source for funding research and development. Below, we have selected the five most interesting subsidies in the life science and health sector with a deadline in the coming months.

Grants in life sciences and medical technology push the development of tomorrow's technologies, jobs, and well-being. There are many grant possibilities such as Horizon 2020, European Research Council, Eurostars, SME instrument, NIH, STW, NWO,WBSO/RDA, Innovation Credit and IMI. Some of these are available for both academia and industry to fast track research and the development process. With the many funding opportunities available, it may be hard to find and select the most interesting ones. Therefore, we will provide you with the most interesting and relevant funding opportunities in this monthly 'subsidies to watch' news message.  

  1. H2020 - SME instrument Phase I (topics include cell technologies for medical applications, ICT solutions for health, well-being and ageing, support to biotechnology SMEs, nanotechnologies and open disruptive innovation scheme)
    The SME instrument is meant to stimulate the growth of European SMEs. The challenge is to help overcome the current gaps in exploitation of promising research results in ICT for Health, Well-being and Ageing well and to stimulate increased availability and market uptake of relevant ICT products and services. This concerns both interoperable and secure eHealth solutions for consumers and institutional healthcare delivery building on standards and new ICT solutions and innovation ecosystems for ageing well building on open software platforms, in order to deliver new and more efficient care to European citizens and respond to new market opportunities for SMEs.

    Within Phase 1, SMEs can request € 50.000 to perform a commercial feasibility study and develop a business plan. During this phase, a feasibility study shall be developed verifying the technological/practical as well as economic viability of an innovation idea/concept with considerable novelty to the industry sector in which it is presented. This study typically consists of: risk assessment, market study, user involvement, Intellectual Property management, innovation strategy development, partner search.
    Project budget: €50,000. Deadline: May 3, 2016
     
  2. H2020 - NMBP - Second Stage (Analytical techniques and tools in support of nanomaterial risk assessment, Advancing Materials Modelling, Biomaterials for diagnosis and treatment of myelinisation disorders)
    This call addresses nanoformulation of biologicals (like proteins, peptides, nucleic acids and enzymes). Many biomolecules have demonstrated interesting therapeutic activities in vitro, but are too often not drugable. They show disappointing loss of efficacy and/or unacceptable toxicity. With appropriate formulations the biological can be effectively transported through the relevant biological barriers to targeted organs, tissues and cells.
    Project budget: €5 – €7 Million (Total available: 32 Million). Deadline: May 24, 2016
     
  3. H2020 - Fast Track to Innovation
    Fast track to Innovation (FTI) is a pilot programme under Horizon 2020. It provides bottom-up funding for projects which are close to market, meaning market entry has to be achieved within 3 years after the start of a FTI-project. Projects which relate to any field under the specific objective 'Leadership in enabling and industrial technologies' and/or under the priority 'Societal challenges' (e.g. all the Personalised Health and Care calls) can apply for FTI funding. Funding rate for academia is 100%, for industry 70%.
    Project budget: €3 Million (Total available: €100 Million). Deadline: June 1, 2016
     
  4. H2020 - SME Instrument Phase II (topics include cell technologies for medical applications, ICT solutions for health, well-being and ageing, support to biotechnology SMEs, nanotechnologies and open disruptive innovation scheme)
    For the SME Instrument description, see above. SMEs can request up to €5.000.000 to fund one or more clinical trials. Funding technology or product development is only possible to a very limited extent. Within Phase 2, the Commission considers that proposals requesting a contribution from the EU of between €0.5 and 2.5 million would allow phase 2 to be addressed appropriately. Depending on the topic funding is 100% or 70%.
    Project budget: €0,5 -€5 Million. Deadline: June 15, 2016
     
  5. ZonMw - ERA-CVD Joint Transnational Call 2016 - Second stage
    ERA-CVD is an H2020 European Research Area Network, co-funded by the European Commission, dedicated at cardiovascular diseases. ZonMw and Hartstichting are the Dutch partners in this initiative. The aim of this call is to enable researchers in different countries to effectively collaborate and share expertise in the field of heart failure. Particularly, projects should focus on diagnosis and therapy for heart failure, as well as involve the association between causative factors and organ dysfunction in the development and progression of heart failure.
    Project budget: €400,000 (Total available: €1.25 Million). Deadline: June 17, 2016

To keep updated with the latest news on new calls, deadlines and other opportunities, take a look at our funding database or contact one of our consultants.

Share this